Hospitalisation among vaccine breakthrough COVID-19 infections
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00558-2/fulltext
Robust vaccine efficacies at preventing severe symptomatic disease
Breakthrough SARS-CoV-2 infections in fully vaccinated
https://covid.joinzoe.com/post/worryingly-close-to-100-000-new-cases-a-day
Impact of vaccination on admission to hospital
Patients with confirmed SARS-CoV-2 infection
Yale New Haven Health System, Connecticut
Between March 23 and July 1, 2021
Patients were considered fully vaccinated 14 days after second dose
969 patients were admitted PCR positive
172 (18%) of 969 patients had received at least one vaccine dose
103 had received a partial vaccine course
15 had received a complete course
54 were fully vaccinated
Among the 54
25 (46%) patients were asymptomatic
4 (7%) had mild disease
11 (20%) had moderate disease
14 (26%) had severe or critical illness
4 (7%) required ICU
1 required ventilation
3 died
Among those with severe or critical illness
Median age 80·5 years
Pre-existing comorbidities in the 14 patients with severe or critical illness
Body–mass index more than 25 kg/m² (n=9)
Cardiovascular disease (n=12)
Lung disease (n=7)
Malignancy (n=4)
Type 2 diabetes (n=7)
Immunosuppressive agent (n=4)
Difference between vaccines
13 of 14 patients had received BNT162b2, Pfizer
1 of the 14 had received mRNA-1273, Moderna
0 of the 14 had received Ad.26. COV2.S, J and J
May 17, 2021, vaccine doses in Connecticut
Pfizer, 1, 358, 175
Moderna, 1, 044, 420
J and J, 267, 000
0 Comments